ID

35506

Description

Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Colorectal, Non-small Cell Lung and Pancreatic Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02450656

Link

https://clinicaltrials.gov/show/NCT02450656

Keywords

Versions (1)
  1. 3/6/19 3/6/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

March 6, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Colorectal Neoplasms NCT02450656

English

Eligibility Colorectal Neoplasms NCT02450656

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
histological or cytological proof of advanced crc, nsclc or pancreatic cancer; for part b: treated with first line therapy for metastatic disease only.
Description

Colorectal Carcinoma Advanced | Non-Small Cell Lung Carcinoma Advanced | Pancreatic carcinoma Advanced | First line treatment Neoplasm Metastasis

Data type

boolean

Alias
UMLS CUI [1,1]
C0009402
UMLS CUI [1,2]
C0205179
UMLS CUI [2,1]
C0007131
UMLS CUI [2,2]
C0205179
UMLS CUI [3,1]
C0235974
UMLS CUI [3,2]
C0205179
UMLS CUI [4,1]
C1708063
UMLS CUI [4,2]
C0027627
written documentation of a known pathogenic kras (exon 2, 3 or 4) mutation and pik3ca wildtype (defined as absence of mutations in exon 9 and 20)
Description

KRAS Exon 2 Mutation | KRAS Exon 3 Mutation | KRAS Exon 4 Mutation | PIK3CA gene Wild Type

Data type

boolean

Alias
UMLS CUI [1]
C4525999
UMLS CUI [2]
C4528684
UMLS CUI [3]
C4526000
UMLS CUI [4,1]
C1335212
UMLS CUI [4,2]
C1883559
able and willing to give written informed consent
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
able and willing to undergo blood sampling for pk and pd analysis
Description

Blood sampling

Data type

boolean

Alias
UMLS CUI [1]
C0005834
life expectancy >=3 months allowing adequate follow up of toxicity evaluation and antitumor activity.
Description

Life Expectancy allowing Follow-up

Data type

boolean

Alias
UMLS CUI [1,1]
C0023671
UMLS CUI [1,2]
C0683607
UMLS CUI [1,3]
C3274571
who performance status of 0 or 1.
Description

WHO performance status scale

Data type

boolean

Alias
UMLS CUI [1]
C1298650
able and willing to undergo a tumor biopsies prior to start, after two weeks (part a only) and upon progression of disease
Description

Tumor Biopsy | Disease Progression

Data type

boolean

Alias
UMLS CUI [1,1]
C0027651
UMLS CUI [1,2]
C0005558
UMLS CUI [2]
C0242656
measurable disease according to recist 1.1
Description

Measurable Disease

Data type

boolean

Alias
UMLS CUI [1]
C1513041
adequate organ system function measured by laboratory values
Description

Organ function Laboratory Procedures

Data type

boolean

Alias
UMLS CUI [1,1]
C0678852
UMLS CUI [1,2]
C0022885
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
any treatment with investigational drugs within 30 days prior to receiving the first dose of investigational treatment.
Description

Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1]
C0013230
history of another malignancy exception part a: patients who have been disease-free for at least 3 years, or patients with a history of completely resected non-melanoma skin cancer and/or patients with indolent second malignancies are eligible. exception part b: adequately treated carcinoma in situ of the cervix and adequately treated basal cell carcinoma of the skin. 3. symptomatic or untreated leptomeningeal disease.
Description

Cancer Other | Exception Disease Free Duration | Exception Skin carcinoma Resected Completely | Exception Second malignancy indolent | Exception Carcinoma in situ of uterine cervix Treated | Exception Basal cell carcinoma Treated | Leptomeningeal Neoplasm Symptomatic | Leptomeningeal Neoplasm Untreated

Data type

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0012634
UMLS CUI [2,3]
C0332296
UMLS CUI [2,4]
C0449238
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0699893
UMLS CUI [3,3]
C1521996
UMLS CUI [3,4]
C0205197
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0085183
UMLS CUI [4,3]
C0234227
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0851140
UMLS CUI [5,3]
C1522326
UMLS CUI [6,1]
C1705847
UMLS CUI [6,2]
C0007117
UMLS CUI [6,3]
C1522326
UMLS CUI [7,1]
C0751297
UMLS CUI [7,2]
C0231220
UMLS CUI [8,1]
C0751297
UMLS CUI [8,2]
C0332155
symptomatic brain metastasis.
Description

Metastatic malignant neoplasm to brain Symptomatic

Data type

boolean

Alias
UMLS CUI [1,1]
C0220650
UMLS CUI [1,2]
C0231220
patients previously treated with any drug combination known to interfere with egfr, her2, her3, her4 or mapk- and pi3k-pathway components, including inhibitors of pten, pi3k, akt, mtor, braf, mek and erk.
Description

Combined Modality Therapy Interferes with Epidermal Growth Factor Receptor | Combined Modality Therapy Interferes with HER2 | Combined Modality Therapy Interferes with HER3 | Combined Modality Therapy Interferes with HER4 | Combined Modality Therapy Interferes with Mitogen-Activated Protein Kinases Component | Combined Modality Therapy Interferes with Phosphatidylinositol 3-Kinases Component | Combined Modality Therapy Interferes with PTEN inhibitors | Combined Modality Therapy Interferes with Phosphatidylinositol 3-Kinases inhibitors | Combined Modality Therapy Interferes with AKT1 inhibitors | Combined Modality Therapy Interferes with AKT2 inhibitors | Combined Modality Therapy Interferes with AKT3 inhibitors | Combined Modality Therapy Interferes with mTOR Inhibitor | Combined Modality Therapy Interferes with B-Raf inhibitor | Combined Modality Therapy Interferes with MEK Inhibitor

Data type

boolean

Alias
UMLS CUI [1,1]
C0009429
UMLS CUI [1,2]
C0521102
UMLS CUI [1,3]
C0034802
UMLS CUI [2,1]
C0009429
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C0069515
UMLS CUI [3,1]
C0009429
UMLS CUI [3,2]
C0521102
UMLS CUI [3,3]
C0072460
UMLS CUI [4,1]
C0009429
UMLS CUI [4,2]
C0521102
UMLS CUI [4,3]
C0812267
UMLS CUI [5,1]
C0009429
UMLS CUI [5,2]
C0521102
UMLS CUI [5,3]
C0752312
UMLS CUI [5,4]
C1705248
UMLS CUI [6,1]
C0009429
UMLS CUI [6,2]
C0521102
UMLS CUI [6,3]
C2936824
UMLS CUI [6,4]
C1705248
UMLS CUI [7,1]
C0009429
UMLS CUI [7,2]
C0521102
UMLS CUI [7,3]
C0694888
UMLS CUI [7,4]
C0243077
UMLS CUI [8,1]
C0009429
UMLS CUI [8,2]
C0521102
UMLS CUI [8,3]
C2936824
UMLS CUI [8,4]
C0243077
UMLS CUI [9,1]
C0009429
UMLS CUI [9,2]
C0521102
UMLS CUI [9,3]
C0812228
UMLS CUI [9,4]
C0243077
UMLS CUI [10,1]
C0009429
UMLS CUI [10,2]
C0521102
UMLS CUI [10,3]
C0812230
UMLS CUI [10,4]
C0243077
UMLS CUI [11,1]
C0009429
UMLS CUI [11,2]
C0521102
UMLS CUI [11,3]
C1332074
UMLS CUI [11,4]
C0243077
UMLS CUI [12,1]
C0009429
UMLS CUI [12,2]
C0521102
UMLS CUI [12,3]
C2746052
UMLS CUI [13,1]
C0009429
UMLS CUI [13,2]
C0521102
UMLS CUI [13,3]
C4521853
UMLS CUI [14,1]
C0009429
UMLS CUI [14,2]
C0521102
UMLS CUI [14,3]
C2347168
history of interstitial lung disease or pneumonitis
Description

Lung Diseases, Interstitial | Pneumonitis

Data type

boolean

Alias
UMLS CUI [1]
C0206062
UMLS CUI [2]
C3714636
radio-, immuno- or chemotherapy within the last 2 weeks prior to receiving the first dose of investigational treatment. palliative radiation (1x 8gy) is allowed.
Description

Therapeutic radiology procedure | Immunotherapy | Chemotherapy | Palliative Radiation Therapy allowed

Data type

boolean

Alias
UMLS CUI [1]
C1522449
UMLS CUI [2]
C0021083
UMLS CUI [3]
C0392920
UMLS CUI [4,1]
C3898008
UMLS CUI [4,2]
C0683607
opthalmological diseases
Description

Disorder of eye

Data type

boolean

Alias
UMLS CUI [1]
C0015397
patients with left ventricular ejection fraction (lvef) < 55%
Description

Left ventricular ejection fraction

Data type

boolean

Alias
UMLS CUI [1]
C0428772
patients with cardiac comorbidities
Description

Comorbidity Cardiac

Data type

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C1522601
concomitant or recent use (in the past 14 days) of strong inhibitors and inducers of cyp1a2, cyp2c19, cyp3a4, 3a5 and p-glycoprotein (p-gp)
Description

CYP1A2 Inhibitors | CYP1A2 Inducers | CYP2C19 Inhibitors | CYP2C19 Inducers | CYP3A4 Inhibitors | CYP3A4 Inducers | CYP3A5 Inhibitors | CYP3A5 Inducers | P-Glycoprotein Inhibitors | P-Glycoprotein Inducers

Data type

boolean

Alias
UMLS CUI [1]
C3850068
UMLS CUI [2]
C3850050
UMLS CUI [3]
C3850059
UMLS CUI [4]
C3850047
UMLS CUI [5]
C3850053
UMLS CUI [6]
C3850041
UMLS CUI [7]
C3850054
UMLS CUI [8]
C3850043
UMLS CUI [9]
C3500483
UMLS CUI [10]
C3883353
Back to the top of the page

Similar models

Eligibility Colorectal Neoplasms NCT02450656

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Colorectal Carcinoma Advanced | Non-Small Cell Lung Carcinoma Advanced | Pancreatic carcinoma Advanced | First line treatment Neoplasm Metastasis
Item
histological or cytological proof of advanced crc, nsclc or pancreatic cancer; for part b: treated with first line therapy for metastatic disease only.
boolean
C0009402 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C0007131 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
C0235974 (UMLS CUI [3,1])
C0205179 (UMLS CUI [3,2])
C1708063 (UMLS CUI [4,1])
C0027627 (UMLS CUI [4,2])
KRAS Exon 2 Mutation | KRAS Exon 3 Mutation | KRAS Exon 4 Mutation | PIK3CA gene Wild Type
Item
written documentation of a known pathogenic kras (exon 2, 3 or 4) mutation and pik3ca wildtype (defined as absence of mutations in exon 9 and 20)
boolean
C4525999 (UMLS CUI [1])
C4528684 (UMLS CUI [2])
C4526000 (UMLS CUI [3])
C1335212 (UMLS CUI [4,1])
C1883559 (UMLS CUI [4,2])
Informed Consent
Item
able and willing to give written informed consent
boolean
C0021430 (UMLS CUI [1])
Blood sampling
Item
able and willing to undergo blood sampling for pk and pd analysis
boolean
C0005834 (UMLS CUI [1])
Life Expectancy allowing Follow-up
Item
life expectancy >=3 months allowing adequate follow up of toxicity evaluation and antitumor activity.
boolean
C0023671 (UMLS CUI [1,1])
C0683607 (UMLS CUI [1,2])
C3274571 (UMLS CUI [1,3])
WHO performance status scale
Item
who performance status of 0 or 1.
boolean
C1298650 (UMLS CUI [1])
Tumor Biopsy | Disease Progression
Item
able and willing to undergo a tumor biopsies prior to start, after two weeks (part a only) and upon progression of disease
boolean
C0027651 (UMLS CUI [1,1])
C0005558 (UMLS CUI [1,2])
C0242656 (UMLS CUI [2])
Measurable Disease
Item
measurable disease according to recist 1.1
boolean
C1513041 (UMLS CUI [1])
Organ function Laboratory Procedures
Item
adequate organ system function measured by laboratory values
boolean
C0678852 (UMLS CUI [1,1])
C0022885 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Investigational New Drugs
Item
any treatment with investigational drugs within 30 days prior to receiving the first dose of investigational treatment.
boolean
C0013230 (UMLS CUI [1])
Cancer Other | Exception Disease Free Duration | Exception Skin carcinoma Resected Completely | Exception Second malignancy indolent | Exception Carcinoma in situ of uterine cervix Treated | Exception Basal cell carcinoma Treated | Leptomeningeal Neoplasm Symptomatic | Leptomeningeal Neoplasm Untreated
Item
history of another malignancy exception part a: patients who have been disease-free for at least 3 years, or patients with a history of completely resected non-melanoma skin cancer and/or patients with indolent second malignancies are eligible. exception part b: adequately treated carcinoma in situ of the cervix and adequately treated basal cell carcinoma of the skin. 3. symptomatic or untreated leptomeningeal disease.
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0012634 (UMLS CUI [2,2])
C0332296 (UMLS CUI [2,3])
C0449238 (UMLS CUI [2,4])
C1705847 (UMLS CUI [3,1])
C0699893 (UMLS CUI [3,2])
C1521996 (UMLS CUI [3,3])
C0205197 (UMLS CUI [3,4])
C1705847 (UMLS CUI [4,1])
C0085183 (UMLS CUI [4,2])
C0234227 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C0851140 (UMLS CUI [5,2])
C1522326 (UMLS CUI [5,3])
C1705847 (UMLS CUI [6,1])
C0007117 (UMLS CUI [6,2])
C1522326 (UMLS CUI [6,3])
C0751297 (UMLS CUI [7,1])
C0231220 (UMLS CUI [7,2])
C0751297 (UMLS CUI [8,1])
C0332155 (UMLS CUI [8,2])
Metastatic malignant neoplasm to brain Symptomatic
Item
symptomatic brain metastasis.
boolean
C0220650 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
Combined Modality Therapy Interferes with Epidermal Growth Factor Receptor | Combined Modality Therapy Interferes with HER2 | Combined Modality Therapy Interferes with HER3 | Combined Modality Therapy Interferes with HER4 | Combined Modality Therapy Interferes with Mitogen-Activated Protein Kinases Component | Combined Modality Therapy Interferes with Phosphatidylinositol 3-Kinases Component | Combined Modality Therapy Interferes with PTEN inhibitors | Combined Modality Therapy Interferes with Phosphatidylinositol 3-Kinases inhibitors | Combined Modality Therapy Interferes with AKT1 inhibitors | Combined Modality Therapy Interferes with AKT2 inhibitors | Combined Modality Therapy Interferes with AKT3 inhibitors | Combined Modality Therapy Interferes with mTOR Inhibitor | Combined Modality Therapy Interferes with B-Raf inhibitor | Combined Modality Therapy Interferes with MEK Inhibitor
Item
patients previously treated with any drug combination known to interfere with egfr, her2, her3, her4 or mapk- and pi3k-pathway components, including inhibitors of pten, pi3k, akt, mtor, braf, mek and erk.
boolean
C0009429 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C0034802 (UMLS CUI [1,3])
C0009429 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C0069515 (UMLS CUI [2,3])
C0009429 (UMLS CUI [3,1])
C0521102 (UMLS CUI [3,2])
C0072460 (UMLS CUI [3,3])
C0009429 (UMLS CUI [4,1])
C0521102 (UMLS CUI [4,2])
C0812267 (UMLS CUI [4,3])
C0009429 (UMLS CUI [5,1])
C0521102 (UMLS CUI [5,2])
C0752312 (UMLS CUI [5,3])
C1705248 (UMLS CUI [5,4])
C0009429 (UMLS CUI [6,1])
C0521102 (UMLS CUI [6,2])
C2936824 (UMLS CUI [6,3])
C1705248 (UMLS CUI [6,4])
C0009429 (UMLS CUI [7,1])
C0521102 (UMLS CUI [7,2])
C0694888 (UMLS CUI [7,3])
C0243077 (UMLS CUI [7,4])
C0009429 (UMLS CUI [8,1])
C0521102 (UMLS CUI [8,2])
C2936824 (UMLS CUI [8,3])
C0243077 (UMLS CUI [8,4])
C0009429 (UMLS CUI [9,1])
C0521102 (UMLS CUI [9,2])
C0812228 (UMLS CUI [9,3])
C0243077 (UMLS CUI [9,4])
C0009429 (UMLS CUI [10,1])
C0521102 (UMLS CUI [10,2])
C0812230 (UMLS CUI [10,3])
C0243077 (UMLS CUI [10,4])
C0009429 (UMLS CUI [11,1])
C0521102 (UMLS CUI [11,2])
C1332074 (UMLS CUI [11,3])
C0243077 (UMLS CUI [11,4])
C0009429 (UMLS CUI [12,1])
C0521102 (UMLS CUI [12,2])
C2746052 (UMLS CUI [12,3])
C0009429 (UMLS CUI [13,1])
C0521102 (UMLS CUI [13,2])
C4521853 (UMLS CUI [13,3])
C0009429 (UMLS CUI [14,1])
C0521102 (UMLS CUI [14,2])
C2347168 (UMLS CUI [14,3])
Lung Diseases, Interstitial | Pneumonitis
Item
history of interstitial lung disease or pneumonitis
boolean
C0206062 (UMLS CUI [1])
C3714636 (UMLS CUI [2])
Therapeutic radiology procedure | Immunotherapy | Chemotherapy | Palliative Radiation Therapy allowed
Item
radio-, immuno- or chemotherapy within the last 2 weeks prior to receiving the first dose of investigational treatment. palliative radiation (1x 8gy) is allowed.
boolean
C1522449 (UMLS CUI [1])
C0021083 (UMLS CUI [2])
C0392920 (UMLS CUI [3])
C3898008 (UMLS CUI [4,1])
C0683607 (UMLS CUI [4,2])
Disorder of eye
Item
opthalmological diseases
boolean
C0015397 (UMLS CUI [1])
Left ventricular ejection fraction
Item
patients with left ventricular ejection fraction (lvef) < 55%
boolean
C0428772 (UMLS CUI [1])
Comorbidity Cardiac
Item
patients with cardiac comorbidities
boolean
C0009488 (UMLS CUI [1,1])
C1522601 (UMLS CUI [1,2])
CYP1A2 Inhibitors | CYP1A2 Inducers | CYP2C19 Inhibitors | CYP2C19 Inducers | CYP3A4 Inhibitors | CYP3A4 Inducers | CYP3A5 Inhibitors | CYP3A5 Inducers | P-Glycoprotein Inhibitors | P-Glycoprotein Inducers
Item
concomitant or recent use (in the past 14 days) of strong inhibitors and inducers of cyp1a2, cyp2c19, cyp3a4, 3a5 and p-glycoprotein (p-gp)
boolean
C3850068 (UMLS CUI [1])
C3850050 (UMLS CUI [2])
C3850059 (UMLS CUI [3])
C3850047 (UMLS CUI [4])
C3850053 (UMLS CUI [5])
C3850041 (UMLS CUI [6])
C3850054 (UMLS CUI [7])
C3850043 (UMLS CUI [8])
C3500483 (UMLS CUI [9])
C3883353 (UMLS CUI [10])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial